There is growing evidence that Lp(a) has an impact on cardiovascular disease, and tyrosine oligonucleotide (ASO) drugs have emerged as a promising method to reduce Lp(a) levels (clearance conditions). The gene discussed is LPA; the disease is cardiovascular disorder.